Fig. 5: Matrix-M–induced IL-18 release is NLRP3 inflammasome independent. | npj Vaccines

Fig. 5: Matrix-M–induced IL-18 release is NLRP3 inflammasome independent.

From: Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization

Fig. 5

BMDCs were either non-primed (A–D) or LPS-primed (A). BMDCs were treated with increasing doses of Matrix-M, Matrix-A, or Matrix-C for 24 hours. Released IL-18 levels were measured by ELISA. Before treatment with Matrix adjuvants, cells were pretreated for 1 h with V-ATPase inhibitor bafilomycin A1 (BafA1) (B) or NLRP3-assembly inhibitor MCC950 (C) at the indicated concentration. Similarly, IL-18 levels were measured in NLRP3-deficient and wild-type (WT, C57BL/6) BMDCs after Matrix adjuvant treatment (D). Results are shown as mean ± SD of three independent experiments.

Back to article page